Evidence map›Paper›PMID 30421160›Full record

ArticleJournal of neuro-oncology2019

Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden.

Ann Olsson, Liacine Bouaoun, Anssi Auvinen, Maria Feychting, Christoffer Johansen, Tiit Mathiesen, Beatrice Melin, Anna Lahkola, Suvi Larjavaara, Anne-Sophie Villegier and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Comment on Choi, Y.-J., et al. Cellular Phone Use and Risk of Tumors: Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 4 countries.

Ann OlssonSection of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France. olssona@iarc.fr.ORCID http://orcid.org/0000-0001-6498-2259
Liacine BouaounSection of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France.
Anssi AuvinenFaculty of Social Sciences, Health Sciences, University of Tampere, Tampere, Finland.
Maria FeychtingInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Christoffer JohansenOncology Clinic, 5073 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Tiit MathiesenDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Beatrice MelinDepartment of Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden.
Anna LahkolaRadiation and Nuclear Safety Authority (STUK), Helsinki, Finland.
Suvi LarjavaaraHelsinki University Hospital, Helsinki, Finland.
Anne-Sophie VillegierINERIS, Toxicologie Expérimentale, Verneuil-en-Halatte, France.
Graham ByrnesSection of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France.
Isabelle DeltourSection of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France.
Joachim SchüzSection of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France.
Centre international de recherche sur le cancer · FRUniversity of Copenhagen · DKHelsinki University Hospital · FIInstitut national de l'environnement industriel et des risques · FRKarolinska Institutet · SERadiation and Nuclear Safety Authority · FITampere University · FIUmeå University · SE

Funding

World Health Organization 001
6 · The paper itself

Abstract

purposeGliomas are the most common cancer of the brain, with a poor prognosis in particular for glioblastoma. In 2014, a study suggested reduced survival in relation to latency of mobile phone use among glioblastoma patients. A joint epidemiological/experimental project to study effects of RF-EMF on tumor development and progression was established. The current analysis relates to the epidemiological part and addresses whether pre-diagnostic mobile phone use was associated with survival among glioma patients.

methodsGlioma cases (n = 806) previously enrolled in a collaborative population-based case-control study in Denmark, Finland and Sweden were followed up for survival. Vital status, date of death, date of emigration, or date last known to be alive was obtained based on registry linkages with a unique personal ID in each country. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) stratified by country. Covariates investigated were sex, age, education, histology, treatment, anatomic location and marital status.

resultsNo indication of reduced survival among glioblastoma patients was observed for various measures of mobile phone use (ever regular use, time since start of regular use, cumulative call time overall or in the last 12 months) relative to no or non-regular use. All significant associations suggested better survival for mobile phone users. Results were similar for high-grade and low-grade gliomas.

conclusionsWe found no evidence of reduced survival among glioma patients in relation to previous mobile phone use.

Indexed as

Cell Phone UseAdolescentAdultAgedBrain NeoplasmsCase-Control StudiesDenmarkFemaleFinlandGliomaHumansMaleMiddle AgedRadio WavesSwedenYoung AdultCase–control studiesGliomaMobile phonesRadiofrequency electromagnetic fieldsSurvival

Identifiers

PMID30421160
OpenAlexW2901716725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.